Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant Tamoxifen mono-therapy: A DBCG study

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lyng, Maria B ^a   Lænkholm, Anne Vibeke ^b   Søkilde, Rolf ^c   Gravgaard, Karina H ^a   Litman, Thomas ^c   Ditzel, Henrik J ^a,d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b SLAGELSE HOSPITAL   (Denmark)

^c Exiqon AS   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 7; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STEM CELL; COHORT ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PREDICTION; RNA ANALYSIS; TREATMENT OUTCOME; BREAST TUMOR; CLUSTER ANALYSIS; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84862109179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036170     Document Type: Article

References (32)

1. Blamey RW, (2002) Guidelines on endocrine therapy of breast cancer EUSOMA. Eur J Cancer 38: 615-634.
2. Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
3. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139.
4. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, et al. (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492.
5. Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, et al. (2008) BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. SABCS, abstract 13: abstracts2view.com/sabcs/view.php? nu = SABCS08L_ 553 BIG I-98 Collaborative, International Breast Cancer Study Group Bern.
6. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs- microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
7. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
8. Adams BD, Furneaux H, White BA, (2007) The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21: 1132-1147.
9. Tessel MA, Krett NL, Rosen ST, (2010) Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol.
10. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, et al. (2007) Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619: 30-37.
11. Masri S, Liu Z, Phung S, Wang E, Yuan YC, et al. (2010) The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat 124: 89-99.
12. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, et al. (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903.
13. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, et al. (2010) Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057.
14. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, et al. (2011) MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 30: 822-831.
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
16. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, et al. (2011) Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer. PLoS One 6: e20980.
17. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, et al. (2009) Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 69: 8332-8340.
18. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, et al. (2008) The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 47: 506-524.
19. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, et al. (2009) miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 37: D98-104.
20. Andersen J, Kamby C, Ejlertsen B, Cold S, Ewertz M, et al. (2008) Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol 47: 718-724.
21. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.
22. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, et al. (2011) MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71: 4443-4453.
23. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
24. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
25. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, et al. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199-205.
26. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831.
27. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, et al. (2010) MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat.
28. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE, (2009) Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res 11: R11.
29. Citri A, Yarden Y, (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
30. Lyng MB, Lænkholm AV, Tan Q, Vach W, Gravgaard KH, et al. (2011) Prediction of outcome of Tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients as determined by focused gene expression signature (Submitted).
31. Elston CW, Ellis IO, (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19; 403-410. Histopathology 41: 151-2, discussion.
32. O'Brien CS, Howell SJ, Farnie G, Clarke RB, (2009) Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 14: 45-54.